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Abstract: New techniques are on the horizon for the detection of small leukemic clones in both, acute
leukemias and myeloproliferative disorders. A promising approach is based on digital polymerase
chain reaction (PCR). Digital PCR (dPCR) is a breakthrough technology designed to provide absolute
nucleic acid quantification. It is particularly useful to detect a low amount of target and therefore
it represents an alternative method for detecting measurable residual disease (MRD). The main
advantages are the high precision, the very reliable quantification, the absolute quantification without
the need for a standard curve, and the excellent reproducibility. Nowadays the main disadvantages of
this strategy are the costs that are still higher than standard qPCR, the lack of standardized methods,
and the limited number of laboratories that are equipped with instruments for dPCR. Several studies
describing the possibility and advantages of using digital PCR for the detection of specific leukemic
transcripts or mutations have already been published. In this review we summarize the available
data on the use of dPCR in acute myeloid leukemia and myeloproliferative disorders.
Keywords: digital PCR; acute myeloid leukemia; chronic myeloproliferative disorders; minimal
residual disease
1. Introduction
Polymerase chain reaction (PCR) is a revolutionary method for DNA amplification set up in 1985
by Kary Mullis, that allows the quantification of nucleic acids by amplification with the enzyme DNA
polymerase [1].
The conventional assay is based on the principle that amplification of the nucleic acid is exponential
thus it can be quantified by comparing the number of amplification cycles and the amount of PCR
end-products to those of a reference sample [2–4].
In a conventional PCR, a solution of template DNA, DNA polymerase, deoxyribonucleotide
triphosphates (dNTPs), primers, and buffer solution are subjected to a series of thermal cycles to
amplify millions of copies of a template DNA [2–4].
In the current modified version of the PCR, the first step of a thermal cycle begins with a process
called initialization or hot start to activate the polymerase at a temperature ranging from 94 ◦C to
96 ◦C. This step is followed by a denaturation step at high temperature between 93 ◦C and 98 ◦C. This
step breaks the bonds in double stranded DNA (dsDNA) thus generating two single-stranded DNA
(ssDNA) molecules. After denaturation, a phase called annealing starts at lower temperature. Primers
are annealed to complementary sequences of the single-stranded DNA molecule. Subsequently the
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PCR mixture is heated to allow incomplete DNA sequence to be extended by the DNA polymerase in
the presence of free dNTPs thus generating a new double-stranded DNA.
Despite the high level of sensitivity of this method, the evaluation of the amount of transcript can
be hampered by many factors that can lead to inaccuracies. Among these, the low initial concentration
of target molecules may not be amplified to detectable levels. In addition, the PCR amplification
product can reach a plateau after a certain number of cycles. Finally, PCR amplification efficiency can
differ in different samples. All these limits can impact on the accuracy of the quantification of the
nucleic acid.
Real Time quantitative PCR (qPCR) represents the evolution of standard PCR. With this technique
the products are continuously monitored throughout the reaction cycles using fluorescent dyes [5].
The initial amount of DNA template can be established by comparing the fluorescence output
curve of the qPCR with a standard curve generated with different known initial numbers of DNA
copies. The cycle threshold (Ct) is defined as the number of cycles required for the fluorescent signal to
cross the threshold and to become detectable. Ct levels are inversely proportional to the amount of
target nucleic acid in the sample.
The qPCR technique is more accurate than standard PCR and finds application in molecular
diagnosis of many hematological malignancies and in the detection of a low amount of residual
disease [6].
Nowadays, due to the high level of sensitivity, the qPCR technique, together with multiparameter
flow cytometry (MFC) is considered the gold standard for the detection of malignant cells in different
types of hematological malignancies [6].
2. Digital PCR
Digital PCR (dPCR) represents an innovative evolution of qPCR with many practical advantages
over qPCR. Although initially described in 1999 [7] by Vogelstein and Kinzler, dPCR has become only
recently a reliable and applicable tool. The first report [7] described the successful detection of Ras
mutations with a high level of sensitivity in a cohort of patients with colorectal cancer [7]. With this
method the exponential signal of PCR is converted into a linear digital signal which is most suitable
for identification of genetic mutation.
From the first report in 1999, dPCR has been successfully applied to cancer genome studies. In the
last few years the interest for this method in the hematological setting has progressively increased
as testified by the number of papers in literature reporting the usefulness of this method for the
quantification of specific leukemic aberrations. The main applications include evaluations of gene
expression (e.g., miRNAs), pathogen quantification, rare allele detection, germline and somatic copy
number variation estimation, viral load analysis, and microbial quantification [8].
In dPCR, the polymerase chain reaction mixture along with the necessary fluorophore is
compartmentalized into several smaller units, each unit undergoes the same thermal cycles as
in the case of a conventional PCR. Usually, dPCR employs the same primer sets, fluorescent labels, and
enzymatic reagents as for traditional RT-PCR, unless recommended differently by the manufacturers.
The key element of dPCR is the partition of the sample into thousands of individual PCR reactions in
essence generating a limiting dilution [9]. As for RT-PCR, dPCR offers a highly precise and sensitive
approach with the main advantage over RT-PCR of avoiding the need for a reference or standard
curve. Despite this, it is necessary to admit that the same advantage can be obtained by performing a
duplex-PCR with the inclusion of a reference gene.
Digital PCR method is based on three main points: the compartmentalization of the target, PCR
on each single molecule and Poisson statistics (Figure 1). Following partition and amplification, the
negative fraction is used to generate an absolute count of the number of target molecules in the
sample, all without reference to standards or controls [10]. Nowadays, different commercialized
digital PCR platforms are available. The first is based on Chip in a tube design (BioRad-QX200 digital
PCR System, Bio-Rad system, Hercules, CA, USA). The second tool is based on micro-well chip (Life
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Technologies-QuantStudio3D® Digital PCR, Life Technologies, Carlsbad, CA, USA). An additional
platform is based on the microfluidic-chamber (Stilla Technologies-Naica Crystal dPCR, Villejuif,
France and Fluidigm-BioMark® HD, Fluidigm Corporation, San Francisco, CA, USA). Micro-well
chip-based and microfluidic-chamber-based (cdPCR) technology can contain up to a few thousand
individual reactions for each sample. Droplet dPCR (ddPCR) is a method based on emulsion PCR.
The sample is fractionated into 20,000 droplets and the amplification of the template molecules occurs
in each droplet [11]. The high partition of ddPCR, makes this method very sensitive and potentially
useful for both, research and diagnostic purposes. The main advantages of dPCR compared to RT-PCR
are the high precision, the very reliable quantification, the absolute quantification without the need for
a standard curve, and excellent reproducibility [12].
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Figure 1. Comparison of PCR-based techniques. RT-PCR and dPCR using the same amplification
reagents and fluorescent labeling system. In dPCR, the sample is first partitioned such that each
partition contains either a few or no DNA sequences. Fluorescence is measured at the end of the PCR.
In qPCR, the amount of amplified DNA is measured at each cycle during the PCR reaction.
Finally, recent papers have reported the higher tolerance of dPCR as compared to RQ-PCR to
different types of inhibitors that can damage DNA or make DNA less accessible, like salts including
KCl and NaCl, ionic detergents such as sodium deocycholate, sarkosyl, and SDS, ethanol, isopropanol,
and phenol among others. This is mainly due to the compartmentalization of target sequences in
smaller volumes [8,13].
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An increasing number of manuscripts is published every month on the use of dPCR in
hematological diseases. In this review we summarize the current knowledge on dPCR in
myeloid neoplasms.
3. dPCR in Chronic Myeloproliferative Disorders: The Example of Chronic Myeloid Leukemia
(CML)
In chronic myeloid leukemia (CML), the presence of a specific marker, the Philadelphia
chromosome, together with the corresponding molecular marker (BCR-ABL fusion transcripts) provides
a unique opportunity for the monitoring of the disease, at diagnosis and during therapy [14]. Lots of
data clearly show that in CML both, cytogenetic and molecular responses, are strictly correlated to the
final outcome and survival of the patients [15,16]. The use of adequate and standardized methods
allows the degree of responses and the depth of disease reduction at specific time points during
treatment to be established [17–19]. This has become fundamental for a correct clinical management of
CML patients. The efforts to standardize the molecular monitoring and the criteria of response led to
the definition of “optimal response” that may represent not only the highest probability of survival but
also the possibility to discontinue the tyrosine-kinase inhibitor (TKI) treatment and therefore to live in
a treatment-free remission (TFR) status [20,21]. Therefore, at least for some patients, deep degrees of
molecular response, as MR4 and MR4.5, whose precise definition has been recently introduced and
which are prerequisites to try discontinuation, are becoming the target to be achieved even in common
clinical practice [15].
Currently, both European Leukemia Net (ELN) [15] and National Comprehensive Cancer
Network (NCCN) [21] recommend the use of qPCR to monitor MRD or to establish the depth
of molecular response.
With the aim of improving PCR sensitivity to increase the predictive value of molecular response,
several studies compared the use of dPCR and qPCR. In the study published by Goh and colleagues, [22]
forty-three CML patients were screened by conventional qPCR, by replicate qPCR (rRQ-PCR) and
by nanofluidic digital PCR. Interestingly they demonstrated that rRQ-PCR, as well as dPCR with
pre-amplification, has a 2–3 log of improvement compared to conventional RQ-PCR. Twenty-four of 32
PCR negative samples as assayed by conventional qPCR showed detectable BCR–ABL in rRQ-PCR
and/or dPCR. Furthermore they were able to demonstrate that, using dPCR with a pre-amplification
step, the progressive reduction of MRD level could be precisely monitored even when undetectable by
conventional qPCR.
In summary, in this study, both rRQ-PCR and ddPCR succeed in the detection of BCR–ABL
transcripts not detectable in conventional RQ-PCR.
These data showed the potential feasibility of highly sensitive PCR approaches for molecular
monitoring and suggested the clinical relevance for future CML management by allowing further
characterization of patients who achieve PCR negativity by qPCR and who are candidates for
therapy discontinuation.
In 2018 Wang and colleagues [23] analyzed the peripheral blood samples from 61 CML patients
who presented an undetectable level ofBCR-ABL by qPCR after tyrosine kinase inhibitor (TKI) treatment
in three successive analyses performed once every 3 months. In parallel, they measured the fusion
transcript by droplet d-PCR and they found that 18% of the patients tested positive by this analysis.
Importantly, during follow up they documented that the few cases who lost MR4 presented a markedly
increased transcript amount, detected by dd-PCR, a few months before the loss of response. This
increase was not detectable by conventional qPCR. These data led to the initial conclusion that dd-PCR
is more sensitive in measuring deep molecular responses.
Different from what is reported above, the study by Alikian and colleagues [24], by analyzing a
cohort of 70 CML patients, demonstrated that dPCR has a comparable performance to qPCR for the
quantification of BCR-ABL1. Their conclusion is that qPCR already has a high level of sensitivity, close
to the single molecule level.
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4. Digital PCR in Philadelphia Negative Chronic Myeloproliferative Neoplasms (Ph-MPN)
Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are clonal disorders that
present JAK2V617F mutation in a percentage ranging from 50% to 95% of cases [25]. Calreticulin (CALR)
gene mutations have recently been discovered in about 20%–35% of patients affected by essential
thrombocythemia (ET) and primary myelofibrosis (PMF) [26]. An additional percentage of ET patients
presents with MPL mutation [27].
JAK2, CALR, and MPL “driver” mutations can be targeted for diagnosis and sometimes to monitor
the disease response (i.e., after allogeneic stem cell transplantation) although the role of these markers
in the evaluation of clinical response to currently available therapies is still questionable.
Due to the lack of effective therapies, able to induce molecular remission in MPN patients, the
development of techniques for the detection of MRD has not been heavily pushed. Recently, a new
scenario is on the horizon with new targeted therapies available or under development [27].
Furthermore, for myelofibrosis, the allogeneic hematopoietic stem cell transplantation (HSCT)
might be curative [28]. In all these settings a precise evaluation of the kinetics of the disease might
provide relevant information for treatment choices [29].
The clinical relevance of determining JAK2, CALR, and MPL based MRD has been demonstrated
with several therapeutically approaches including interferon alpha, JAK1/2 inhibitors, and allogeneic
stem cell transplantation [30].
Recently few studies have been published comparing qPCR and dPCR for the measurement of
JAK2V617F [31–33].
In the study by Fontanelli [31] and colleagues, 99 patients affected by MPN with JAK2V617F were
evaluated in parallel by means of qPCR and droplet dPCR. This latter showed a higher sensitivity than
qPCR in detecting the mutation. They also confirmed an increased mutant allele burden from ET to PV
and PMF.
Link-Lenczowska and colleagues were able to substantially confirm this finding [32]. They
analyzed 63 MPN patients, six of them treated with ruxolitinib, by qPCR and dPCR. Basically, they
found high concordance between the two methods, both demonstrated to be highly sensitive and both
were capable of detecting the JAK2V617F mutation at diagnosis of MPN with a limit of detection of
0.12% for qPCR and 0.01% for ddPCR. The study suggests an advantage of ddPCR in monitoring MRD
when the allele burden is below the threshold of detection of qPCR.
Finally, the clinical utility of dPCR for JAK2V617F mutation was investigated by Waterhouse and
colleagues [33] in 59 patients with MPN, many of them after hematopoietic stem cell transplantation.
The limit of detection was 0.01% for both qPCR and ddPCR. The JAK2V617F mutation was detected in
43 out of 59 patients by both PCR platforms. However, in 14% of the samples, JAK2V617F mutation
was detected only with ddPCR. Interestingly, all these patients were analyzed shortly after allogeneic
HSCT. Although available data on dPCR for JAK2 detection after HSCT are still immature, this study
suggests an intriguing role of dPCR in the context of myeloproliferative disorders. Similar to JAK2V617F
mutation, the monitoring of CALR mutation might improve the therapeutic strategies. Mansier and
colleagues [34] developed a digital PCR technique that allowed detection of types 1 and 2 CALR
allelic burdens. They found that compared with the commonly used fluorescent PCR analysis, digital
PCR is more precise, reproducible, and accurate. In their hands this method reached a very high
sensitivity being able to detect at least 0.025% CALR mutants. They applied this method to patients
with primary myelofibrosis who underwent hematopoietic stem cell transplant and they were able to
predict relapse according to the reappearance of CALR mutations after HSCT. After the achievement of
dPCR negativity, the reappearance of a low level of mutation, although in a single patient, preceded
the hematologic relapse. This study suggests the possibility of using dPCR for CALR mutation
measurement for MRD detection.
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5. Minimal Residual Disease in Acute Myeloid Leukemias
Currently, the post remission treatment of patients affected by acute myeloid leukemias is based
on the genetic profile of leukemic cells at diagnosis and on the level of minimal residual disease after
induction and consolidation chemotherapy mainly detected by multiparameter flow cytometry and
by q-PCR for the assessment of fusion transcripts levels (i.e., CBFB-MYH11 and RUNX1-RUNX1T1
and PML-RARα) of mutations, mainly NPM1 [35,36]. The issue of MRD monitoring has been recently
addressed by the European Leukemia Net (ELN) [6] in an attempt to standardize the methodology and
to provide suggestion on when and how to monitor MRD.
A new promising approach for the detection of MRD is based on dPCR. We report below the
current knowledge on the use of dPCR for detection of leukemic cells.
6. Digital PCR for Acute Myeloid Leukemia Monitoring: The Case of Acute Promyelocytic
Leukemia
Acute promyelocytic leukemia (APL) is a hematological malignancy commonly associated with the
chromosomal translocation t(15;17)(q24;q21), which involves the promyelocytic leukemia (PML) and
the retinoic acid receptor-α (RARα) genes, resulting in the oncogenic fusion transcript PML-RARα [37].
In acute promyelocytic leukemia, the achievement of PCR negativity for PML-RARα at the end of
consolidation treatment is the most informative in terms of prediction of outcome and it is associated
with a low risk of relapse and a high probability of long-term survival [38,39]. The achievement of PCR
negativity retains its clinical significance independently of the therapeutic strategies, all trans-retinoic
acid (ATRA) associated with chemotherapy or ATRA and arsenic trioxide [38,39].
Recently Brunetti and colleagues [40] investigated the role of droplet dPCR for PML-RARα to
monitor MRD in a cohort of 21 patients affected by APL. Droplet dPCR exhibited a sensitivity and
specificity of 95% and 91% respectively for bcr1 and bcr3 transcripts and showed a good concordance
with qPCR. The authors suggested that one of the main advantages of ddPCR-based monitoring of
MRD is represented by the absolute quantification. They also believe that ddPCR could potentially
provide crucial information for the management of patients whose MRD fluctuates under the level of
detection of qPCR.
Similar results have been reported by Yuan and colleagues [41] in 28 APL patients. They confirmed
the good concordance between ddPCR and qPCR in the detection of PML-RARα in clinical samples,
but showed advantages of dPCR over qPCR in terms of precision, limit of detection, and other basic
performance parameters.
In conclusion, based on the available data, at present dPCR could represent a complementary
approach to monitor MRD in APL, particularly for those patients at high risk of relapse.
7. Acute Myeloid Leukemia with IDH1/IDH2 Mutations
Since the evidence that IDH1/IDH2 genes can be mutated in about 10%–20% of AML, many groups
are investigating the possibility of using IDH1/2 as a marker for MRD detection.
Until now, few data have been generated on the clearance of IDH1/IDH2 after chemotherapy and
during remission and contrasting data are reported in the literature [42,43]. Few studies reported
the stability and suitability of IDH as a marker of MRD [42,44]. Recently Petrova and colleagues [45]
published the evaluation of MRD in 90 patients, 22% of them with IDH1/IDH2 mutations. They based
the assessment on NGS and digital droplet PCR. Many patients presented additional mutations such
as NPM1 or MLL-PDT. They concluded that the persistence of IDH1/2 correlates with the treatment
response, although being less sensitive than NPM1 in predicting relapse.
8. Monitoring C-KIT Exon 17 Mutations by Droplet Digital PCR in Patients with Core-Binding
Factor AML
The cytogenetic aberrations involving core binding factor (CBF) include t(8;21)(q22;q22) and
inv(16)(p13.1q22)/t(16;16) (p13.1;q22) [43]. CBF-AML are considered leukemias with a highly favorable
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prognosis although the outcome is highly impacted by the presence of additional genetic mutations,
as exemplified by the mutation of FLT3, C-KIT, or NRAS gene [46–49]. In particular the mutations of
C-KIT gene that result in the constitutive activation of tyrosine kinase activity have a significant impact
on the prognosis of CBF acute myeloid leukemias. In particular, C-KIT mutations are associated with a
higher incidence of relapse, so that CBF AML with C-KIT mutations are classified into the intermediate
risk group by the NCCN Guideline [46–49]. These mutations are most frequently located in exon 17
(54%) encoding the kinase-activation loop, or in exon 8 (28%) affecting the extracellular portion of
C-KIT receptor [46]. C-KIT mutations have been described initially as a single point mutation but the
detection of double mutations has recently been described in AML patients [48].
Although we still lack solid data generated by qPCR on the prognostic significance of the mutation
burden of c-KIT, an attempt to study the dynamic of the mutated clone has been done by Tan and
colleagues [50]. They investigated the dynamic evolution of CBF-AML clones with C-KIT mutations
by ddPCR combined with sequencing [50]. The study included 75 patients with CBF-AML, 19% of
them with double C-KIT mutation.
Droplet digital PCR revealed that these double mutations can occur in either the same or different
clones. Interestingly, according to the mutation, the clone was shown to present a different sensitivity
to treatment. In particular, C-KITN822 mutation confers to the clone a better response to treatment as
compared to C-KITD816 mutation. Moreover, D816 clone was the predominant clone at relapse. In
addition, patients with double mutation had a better overall survival and event-free survival than
those with a single mutation although the statistical significance was not reached, probably due to the
small sample size. The study demonstrated that ddPCR is an effective method for monitoring clonal
evolution in AML.
9. WT1 Assessment by Digital PCR as a Marker of MRD
The usefulness of WT1 quantitative assessment q-PCR as a marker for measurable residual disease
(MRD) detection in acute myeloid leukemia was demonstrated years ago [51–55]. Many studies
clearly showed that WT1 gene is overexpressed in about 80%–90% of patients affected by AML [51,52].
The persistence of WT1 overexpression after chemotherapy is always indicative of persistence of
leukemic cells [51–55]. Based on current evidence WT1 can be considered a universal marker of AML.
In a European study aimed at standardizing the method used for WT1 measurement, it was shown
that the clearance of the transcript to normal values is highly predictive of relapse [55]. Additional
studies suggested that the persistence of abnormal WT1 values after induction or consolidation impacts
on the probability of relapse. An increase of WT1 levels during follow up always predict leukemia
recurrence [51–55]. The main advantages of WT1 assay are that it can be measured in PB and that the
method has been standardized [55].
Koizumi and colleagues [56] analyzed WT1 by ddPCR and qPCR in 40 peripheral blood and bone
marrow samples obtained from patients affected by acute leukemias and myelodysplastic syndromes.
They found a strong correlation between the two methods (R = 0.99) but they demonstrated that dPCR
is able to accurately detect lower WT1 levels compared to qPCR. Based on these results the authors
concluded that dPCR technology can be utilized to measure WT1 based MRD with high accuracy.
10. dPCR for MRD Detection in the Setting of Allogeneic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation is a consolidated therapy for the cure of
patients with AML. Despite the significant number of patients achieving remission after chemotherapy
and stem cell transplantation, the relapse rate is still significant. Many studies demonstrated that the
presence of MRD both at the time of HSCT or after HSCT is a negative prognostic factor with high
impact on survival [57,58]. Thus, nowadays, the detection of MRD to identify patients at high risk of
relapse is mandatory. Different published studies addressed the issue of improving the sensitivity
of PCR in order to increase the predictive value of the method. Bill and colleagues [59] analyzed
by droplet dPCR the pre-transplant samples, both peripheral blood PB and bone marrow BM) of 51
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nucleophosmin 1 (NPM1)-mutated AML patients transplanted in complete remission. The authors
demonstrated that MRD positive patients have a higher cumulative incidence of relapse and shorter
overall survival. In addition, the patients who are still positive for NPM1 mutation by dPCR before
allogeneic HSCT have a worse prognosis, independently from other known prognostic markers, or
from the conditioning they received. The authors envisage the possibility of using dPCR routinely for
patients with mutated NPM1 to guide treatment and improve patients’ outcomes.
A larger study has been published by Valero-Garcia and colleagues [60]. They compared the
sensitivity and accuracy of qPCR and dPCR and their capacity to predict relapse. They analyzed 28
adult patients who underwent allogeneic HSCT. They detected an increasing mixed chimerism prior
to relapse in 100% of patients who relapsed. Compared with conventional qPCR, dPCR was able
to predict relapse with a median anticipation period of 63 days versus 45.5 days by qPCR. Overall,
56% of the relapses were predicted earlier with dPCR whereas 38% of the relapses where detected
simultaneously using both techniques. In only one case relapse was predicted earlier with qPCR. The
presented data strongly support the notion that dPCR is a powerful tool to predict relapse after HSCT.
A summary of the main targets analyzed by dPCR and qPCR is shown in Table 1.
Table 1. A summary of the main targets analyzed by dPCR and qPCR.
Disease Target Experiment Monitoring
CML Bcr-Abl gene expression levels MRD
MPN Jak2V617F DNA copies detection MRD–HSCT
CALRmut DNA copies detection MRD–HSCT
APL PML/RARα gene expression levels MRD
AML IDH1mut DNA copies detection MRD
IDH2mut DNA copies detection MRD
NPM1mut DNA copies detection MRD–HSCT
11. Chimerism Analysis
Finally, another important diagnostic tool in the setting of allogeneic HSCT is represented by
chimerism analysis. For this purpose George and colleagues [61] set up a ddPCR assay and analyzed
patients who received HSCT. With this method they detected the persistence of recipient cells with
a high level of sensitivity. The techniques currently used to assess chimerism after hematopoietic
stem cell transplantation are capillary electrophoresis analysis of STRs amplified by PCR and qPCR
detection of polymorphic indel loci in the human genome. The main limit of capillary electrophoresis is
the sensitivity. This method can detect chimerism fractions >1% of blood or marrow cells with the risk
of missing clinically relevant low-level recipient cells. The second is a highly sensitive method with the
disadvantage of being characterized by variable efficiency and the need for extensive validation and
standards to be run with each assay [62–64].
The limit of capillary electrophoresis can be clinically relevant in the setting of cellular therapies
that frequently result in microchimerism (donor chimerism <1%) [62].
George and colleagues described a highly sensitive droplet digital PCR assay with good
performance throughout the range of clinically relevant chimerism measurements [64]. They validated
the assay in serially diluted samples. The levels of detection and quantification of the assay were 0.01%.
12. Innovative Application of Digital PCR: The Case of Methylation Analysis
DNA methylation is an epigenetic modification that plays a key role in genome regulation [65].
Aberrant DNA methylation contributes to the genesis of tumors including hematological malignancies
such as acute leukemia and myelodysplastic syndromes [66,67].
The regulation of CpG methylation has been demonstrated to play a role in stem cell maintenance
and differentiation [68]. In hematological malignancies, global aberrant DNA methylation has been
widely documented and it has been associated with disease progression and response to therapy [69,70].
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Therefore, methylation analysis will help to understand the pathogenesis of leukemia and will represent
new therapeutic targets. Alu sequences have been demonstrated to contribute to establish the epigenetic
landscape of cancer cells, and several papers have been focused on this topic [71,72].
Orsini and colleagues [70] developed a new method of investigating Alu differential methylation,
based on droplet digital PCR (ddPCR) technology. Although this method has not been applied to
hematological malignancies and no data are available in this setting, this approach could be potentially
useful to profile patients affected by hematologic disorders including myelodysplastic syndromes
(MDS) for diagnostic and prognostic purposes.
13. Conclusions
A great deal of evidence has encouraged the investigation of dPCR for MRD monitoring in
many hematological malignancies, especially in those patients who can reach very deep molecular
responses with pharmacological or cellular therapies. Examples can be represented by the possibility
to discontinue TKI therapy in CML patients or by the possibility of donor lymphocyte infusions in
patients with detectable MRD after HSCT.
The real advantage of using dPCR will probably become clearer in the next few years with the
improvement of the available strategies and the accumulation of data.
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Abbreviations
PCR polymerase chain reaction
dNTP deoxyribonucleotide triphosphates
dsDNA double stranded DNA
ssDNA single stranded DNA
qPCR quantitative polymerase chain reaction
MFC multiparameter flow cytometry
Ct threshold cycle
dPCR digital polymerase chain reaction
ddPCR droplet digital digital polymerase chain reaction
CML chronic myeloid leukemia
TKI tyrosine kinase inhibitor
TFR treatment free remission
MR molecular remission
MR4 molecular remissionwith 4 logs of transcript reduction
MR4.5 Molecular remissionwith 4.5 logs of transcript reduction
ELN European Leukemia Net
NCCN National Comprehensive Cancer Network
rRQ-PCR replicate quantitative polymerase chain reaction
MPN myeloproliferative neoplasms
JAK2 janus kinase 2
CALR calreticulin
ET essential thrombocythemia
PMF primary myelofibrosis
MRD minimal residual disease
WT1 Wilms tumor gene
HSCT hematopoietic stem cell transplantation
APL acute promyelocytic leukemia
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PML promyelocytic leukemia
RARa retinoic acid receptor alpha
ATRA all trans retinoic acid
IDH1/2 Isocitrate dehydrogenase 1/2
NPM1 nucleophosmin
MDS Myelodysplastic syndromes
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